Publicaciones (50) Publicaciones en las que ha participado algún/a investigador/a

2014

  1. A Mouse Model Uncovers LKB1 as an UVB-Induced DNA Damage Sensor Mediating CDKN1A (p21 WAF1/CIP1 ) Degradation

    PLoS Genetics, Vol. 10, Núm. 10

  2. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial

    Breast, Vol. 23, Núm. 5, pp. 656-662

  3. Advanced extramammary Paget's disease of the groin, penis, and scrotum

    Clinical Medicine Insights: Oncology, Vol. 8, pp. 87-90

  4. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 15, Núm. 11, pp. 1269-1278

  5. Biomarker Analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer

    Journal of Clinical Oncology, Vol. 32, Núm. 33, pp. 3753-3761

  6. Breast-conservative surgery followed by radiofrequency ablation of margins decreases the need for a second surgical procedure for close or positive margins

    Clinical Breast Cancer

  7. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: A proof-of-principle

    Annals of Oncology, Vol. 25, Núm. 9, pp. 1729-1735

  8. Carta a un amigo muerto

    Madrid : Fundación Patronato de Huérfanos y Protección Social de Médicos Príncipe de Asturias, 2014

  9. Changes in breast cancer reports after pathology second opinion

    Breast Journal

  10. Dermatitis seborreica

    FMC: Formación Médica Continuada en Atención Primaria, Vol. 21, Núm. 1, pp. 33-37

  11. Dermatitis seborreica

    FMC Formacion Medica Continuada en Atencion Primaria, Vol. 21, Núm. 1, pp. 33-37

  12. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy

    Journal of the National Cancer Institute, Vol. 106, Núm. 11

  13. Effects of fibrosis morphology on reentrant ventricular tachycardia inducibility and simulation fidelity in patient-derived models

    Clinical Medicine Insights: Cardiology, Vol. 8, pp. 1-13

  14. Effects of movement and postural positions in spinal cord stimulation in the new rechargeable systems

    Pain Physician, Vol. 17, Núm. 4, pp. 345-352

  15. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies

    Breast Cancer Research and Treatment, Vol. 148, Núm. 3, pp. 553-561

  16. Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer

    Oncologist, Vol. 19, Núm. 4, pp. 318-327

  17. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing

    Molecular Oncology, Vol. 8, Núm. 1, pp. 150-158

  18. Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: An exploratory analysis of the TRYPHAENA study

    Breast Cancer Research, Vol. 16, Núm. 4

  19. Expert perspectives on biosimilar monoclonal antibodies in breast cancer

    Breast Cancer Research and Treatment, Vol. 144, Núm. 2, pp. 233-239

  20. Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors

    Annals of Oncology, Vol. 25, Núm. 3, pp. 552-563